Lise E.
- Country
- Denmark
- Department
- Oncology
Research Overview
- Tarlatamab plus Durvalumab versus Durvalumab Alone in Patients with Extensive-Stage Small Cell Lung Cancer Following Platinum-Etoposide Therapy
- A Phase II Study of IBI3009 Monotherapy or in Combination with Combination Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
- Sacituzumab Tirumotecan With or Without Bevacizumab Versus Standard of Care in Patients With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following Platinum-Based Chemotherapy
Data & Insights
Has run more than one trial at 81 of 245 partner sites.
Specializations
Oncology and Hematologic Malignancies
Lise EckHoff’s clinical research includes a broad range of malignant diseases managed within oncology, with particular involvement in breast cancer, lung cancer, colorectal cancer, ovarian cancer, and endometrial cancer. The portfolio also extends to lymphoma, leukemia, and multiple myeloma, reflecting interest in both solid tumors and blood cancers.
- Breast cancer
- Non-small cell lung cancer
- Diffuse large B-cell lymphoma
- Acute lymphoblastic leukemia
- Multiple myeloma
Her trial activity also covers advanced and metastatic disease settings, including gastrointestinal cancer, bladder cancer, and prostate cancer, highlighting a strong therapeutic focus on systemic anticancer treatment.
Cardiovascular Medicine and Thrombotic Disease
Another major area of interest is cardiovascular disease, with studies spanning acute coronary syndrome, myocardial infarction, atrial fibrillation, heart failure, and cardiac arrest. The research landscape also includes prevention of recurrent vascular events and management of high-risk cardiometabolic profiles.
- Acute coronary syndromes
- Atrial fibrillation
- Heart failure
- Cardiac arrest
- Atherosclerotic cardiovascular disease
Her involvement extends to thrombosis, stroke, and perioperative cardiovascular complications, indicating a therapeutic interest in both acute care and long-term vascular risk reduction.
Immune-Mediated and Inflammatory Disorders
Lise EckHoff is active in trials addressing autoimmune disease and chronic inflammation, including Crohn’s disease, ulcerative colitis, psoriatic arthritis, systemic lupus erythematosus, and myasthenia gravis. This area also encompasses disorders such as sarcoidosis, vasculitis, and chronic inflammatory demyelinating polyneuropathy.
- Crohn’s disease
- Ulcerative colitis
- Systemic lupus erythematosus
- Chronic inflammatory demyelinating polyneuropathy
- Psoriatic arthritis
Her research also includes asthma, urticaria, and eosinophilic esophagitis, showing a therapeutic span across immune-driven disease in multiple organ systems.
Neurology, Neuro-oncology, and Rare Central Nervous System Disease
Her clinical trial landscape includes neurology and neuro-oncology, with studies in multiple sclerosis, migraine, epilepsy, glioblastoma, diffuse glioma, and medulloblastoma. The portfolio also reaches into pediatric and rare central nervous system tumors.
- Multiple sclerosis
- Glioblastoma
- Diffuse glioma
- Medulloblastoma
- Epilepsy
This area reflects involvement in both disease-modifying therapy and symptom-focused care for complex neurological conditions.
Metabolic, Renal, Pulmonary, and Hepatobiliary Conditions
Her research also spans chronic systemic diseases such as type 2 diabetes, dyslipidemia, chronic kidney disease, IgA nephropathy, and obesity. Additional activity includes idiopathic pulmonary fibrosis, COPD, bronchiectasis, primary sclerosing cholangitis, and alcohol-related liver disease.
- Type 2 diabetes
- Chronic kidney disease
- Idiopathic pulmonary fibrosis
- Primary sclerosing cholangitis
- Alcohol-related liver disease
Her trial activity further includes amyloidosis, mastocytosis, and other multisystem disorders, indicating engagement with both common chronic disease and rarer therapeutic areas.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.